Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | PRF1 | P14222 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020307 | 1.00 | MAPK14 (0.34) | MAPK14ADORA2BHTR1BOPRK1FFAR4 | |
| SCHEMBL12020317 | 1.00 | MAPK14 (0.34) | MAPK14ADORA2BHTR1BOPRK1FFAR4 | |
| SCHEMBL3602017 | 0.89 | ADORA2B (0.43) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL381709 | 0.89 | ADORA2B (0.43) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL252404 | 0.89 | ADORA2B (0.43) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL13390169 | 0.89 | — | — | |
| SCHEMBL12536086 | 0.86 | KDM4E (0.40) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL12534694 | 0.85 | MAPT (0.43) | MAPK14ADORA2BHTR1BOPRK1FFAR4 | |
| SCHEMBL12535075 | 0.85 | MAPT (0.43) | MAPK14ADORA2BHTR1BOPRK1FFAR4 | |
| SCHEMBL12535083 | 0.80 | ADORA1 (0.34) | ADORA2BADORA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8691850-B2 | Substituted phenylaminothiazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-08 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | BAYER HEALTHCARE AG LAW AND PATENTS,PATENTS AND LICENSING (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | ADORA1, ADORA2B, ADORA2A | MAPK14 3046/4885ADORA2B 2/4885HTR1B 61/4885 |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | PAH, TNNT2, VHL | MAPK14 320/4885ADORA2B 2425/4885HTR1B 1807/4885 |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | MAPK14 1195/4885ADORA2B 1900/4885HTR1B 1563/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | MAPK14 673/4885ADORA2B 942/4885HTR1B 1353/4885 |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | AADAC, CYP4X1, AGXT | MAPK14 2133/4885ADORA2B 3694/4885HTR1B 1538/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | MAPK14 2221/4885ADORA2B 3238/4885HTR1B 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.